Rubraca is a cancer medicine for treating high\-grade cancers of the ovary, fallopian tubes (the tubes connecting the ovaries to the uterus) and the peritoneum (the membrane lining the abdomen). It is used as maintenance treatment in patients newly diagnosed with advanced cancer or in patients whose cancer has come back, and in whom the cancer has cleared (partially or completely) after treatment with platinum\-based chemotherapy. Rubraca contains the active substance rucaparib.
Therapeutic Indication
Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high\-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first\-line platinum\-based chemotherapy. Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum\-sensitive relapsed high\-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum\-based chemotherapy.
Therapeutic Area (MeSH)
ATC Code
L01XX
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Rucaparib camsylate | N/A | Rucaparib camsylate |
EMA Name
Rubraca
Medicine Name
Rubraca
Aliases
N/ANo risk management plan link.
